2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com
28 Nov 2022
Phase 2VaccineImmunotherapyClinical ResultASCO
DUBLIN--(BUSINESS WIRE)--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.
This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.
Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitorPD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitorindoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.
Business Questions:
How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitorIDO inhibitor BMS-986205 in patients with advanced bladder cancer?
Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?
What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?
Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitorIDO inhibitor?
Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?
If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?
What are KOLs' opinions on the supply shortages previously reported for the BCGBCG vaccine and are they being addressed?
For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.